Retinal Biologics Market Size, Share, Industry, Forecast and outlook (2023-2030)

Retinal Biologics Market Overview

Global Retinal Biologics Market Poised for Robust Growth with a 6.5% CAGR During 2024-2031

Leading Industry Players Include Amgen, Inc., AbbVie Inc., Novartis International AG, and More

The global Retinal Biologics market is set to witness substantial growth, projecting a high Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period spanning from 2023 to 2030. The competitive landscape is becoming increasingly dynamic with prominent entities like Amgen, Inc., AbbVie Inc., and Novartis International AG playing pivotal roles.

Retinal biologics, derived from living organisms or their derivatives, offer therapeutic solutions for various retinal disorders. Given the delicacy of human eyes and the rising prevalence of retinal health disorders globally, including diabetic retinopathy, infectious retinitis, age-related macular degeneration, and others, the security of retinal health is of paramount importance.

Market Scope and Insights

Market CAGR: 6.5%

Segments Covered: By Drug Class, By Disease Indication, By Distribution Channel, and By Region

Report Insights: Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other Key Insights.

Fastest Growing Region: Asia Pacific

Largest Market Share: North America

To explore further insights, download the sample report.

Industry Dynamics

The growth of the global retinal biologics market is fueled by the increasing incidence of ophthalmic disorders causing chronic retinal diseases worldwide. Factors such as the rising burden of retinal diseases, a growing diabetic patient population, heightened research and development activities, and an increasing number of FDA approvals contribute to the positive market outlook.

However, the industry faces challenges from strict regulatory policies and potential adverse effects of biologics, which may impede growth over the forecast period.

Impact of COVID-19

The perception that individuals with diabetes face a higher risk of infection and severe disease from COVID-19 has impacted the retinal biologics market. While the risk of contracting COVID-19 may not be greater for those with diabetes, the potential for more severe symptoms and complications poses challenges to market growth.

Market Segmentation Analysis

The Diabetic Retinopathy segment is anticipated to exhibit the fastest CAGR during the forecast period (2021-2028). With diabetic retinopathy being a leading cause of global vision loss, the rising prevalence of this condition, coupled with increasing awareness, is expected to drive segment growth.

Geographical Penetration

North America holds the largest market share in the global retinal biologics market. The region's dominance is attributed to a high prevalence of diabetes, with diabetic retinopathy being a leading cause of new cases of blindness. Significant investments in research and development, coupled with risk factors contributing to disease development, are influencing the growth of the U.S. retinal biologics market.

Company and Competitive Landscape

The retinal biologics market is moderately competitive, featuring both local and global companies. Key players contributing to market growth include F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Spark Therapeutics, Novartis International AG, Ocular Therapeutix, Amgen, Inc., among others. Major players adopt growth strategies such as product launches, acquisitions, and collaborations, enhancing the market's global trajectory.

Related Reports:

human chorionic gonadotropic market

basal insulin market

allergic rhinitis treatment market

bleeding disorders treatment market

cerebral palsy treatment market

neurocutaneous syndrome market

About Us -

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Name: Sai K

Designation: Sales & Senior Business Consultant

Email: info@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com